HLL Lifecare Launches AMRIT Plus Premium Pharmacy Chain with Advanced Diagnostics Initiative

IMT News Desk
IMT News Desk
· 2 min read
HLL Lifecare launches AMRIT Plus pharmacy chain with HINDLABS diagnostics & home healthcare, expanding to 550 outlets by 2027 for affordable access.

HLL Lifecare Limited has launched AMRIT Plus, a premium pharmacy chain offering medicines, medical devices and wellness products, along with speciality HINDLABS and home healthcare services, expanding its healthcare access initiatives.

The premium pharmacy chain aims to strengthen healthcare access for millions across India by providing quality medical supplies and wellness products at competitive prices.

This launch follows HLL’s earlier AMRIT (Affordable Medicine and Reliable Implants for Treatment) Pharmacy initiative, which was designed to provide affordable medical items, including medicines, surgical items, consumables and implants for cancer, cardiovascular and other diseases.

The AMRIT Plus expansion represents HLL’s strategy to strengthen its retail presence with an ambitious plan to expand Amrit Pharmacies to 550 outlets by 2027, building on its existing network of affordable medical supply outlets.

The company is also engaged in projects of the National Health Mission across Assam, Maharashtra and Uttar Pradesh under state free diagnostic service initiatives, providing advanced diagnostic infrastructure.

HLL Lifecare, a mini-ratna public sector undertaking under the Union Ministry of Health and Family Welfare, has entered into agreements with state governments, including Maharashtra, to provide quality diagnostic services in around 2,300 state-run health centres, with diagnostic centres becoming operational within 90 days.

The diagnostic centres will offer more than 100 tests from hospital centres, including high-end special molecular diagnostic tests, at rates much lower than market prices, making diagnostic tests available to the public in the remotest villages.

The company is also implementing similar diagnostic projects in Assam, Kerala and Odisha, partnering with the National Health Mission to strengthen public healthcare infrastructure.

Read Next

India’s first focused health AI Conclave unites doctors and AI experts
Featured Article
July 10, 2026

India’s first focused health AI Conclave unites doctors and AI experts

• Global Healthcare Academy hosts HAI Conclave 2026, India’s first national platform dedicated to Healthcare and Artificial Intelligence • Landmark Bengaluru conference brings together healthcare leaders and AI experts to explore how Artificial Intelligence can make healthcare faster, safer and more accessible while keeping patients at the centre of every decision The inaugural edition of the HAI Conclave […]
Article by: IMT News Desk
Fischer Medical Ventures Highlights NYB.AI Partnership as Platform Showcased at NVIDIA GTC Taiwan 2026
News
July 10, 2026

Fischer Medical Ventures Highlights NYB.AI Partnership as Platform Showcased at NVIDIA GTC Taiwan 2026

Fischer Medical Ventures Limited (FMVL) has announced that its strategic partner, Nanyang Biologics, has achieved a major international milestone with its AI-powered molecular research platform, NYB.AI, being featured in the opening showcase at NVIDIA GTC Taiwan 2026, ahead of the keynote address by NVIDIA Founder and CEO Jensen Huang. The recognition places NYB.AI among a […]
Article by: IMT News Desk
Pharma Q1 Margins Seen Under Pressure Despite Revenue Growth: Goldman Sachs
News
July 10, 2026

Pharma Q1 Margins Seen Under Pressure Despite Revenue Growth: Goldman Sachs

Indian pharmaceutical companies are expected to report healthy revenue growth in the first quarter of FY27, but margins are likely to compress as sector profitability comes under pressure. In a recent preview note, Goldman Sachs said it anticipates around 185 basis points year-on-year margin decline for the sector in the June quarter, driven primarily by […]
Article by: IMT News Desk
Dr Reddy’s Delays Semaglutide Supplies After Active Ingredient Quality Issue
News
July 10, 2026

Dr Reddy’s Delays Semaglutide Supplies After Active Ingredient Quality Issue

Dr Reddy’s Laboratories has announced a delay in commercial supplies of its semaglutide product after certain batches were found to be out of specification due to an issue with the active pharmaceutical ingredient (API) used in the drug. The company said it has initiated an investigation into the root cause and is taking corrective measures […]
Article by: IMT News Desk